ABSTRACT
The incidence of unsightly venulectasias and/or telangiectasias on the legs occurs in up to 41% of women and 15% of men (1). The utilization of lasers and intense pulsed light (IPL) sources for the treatment of lower extremity veins has gained increased popularity over the past five years. This technology, driven by consumer demand, has been shown to be effective in treating vessels that are refractory to sclerotherapy, vessels that arise from prior surgical treatment or sclerotherapy (telangiectatic matting or angiogenic flushing), and needle-phobic patients.
